NCT00359086View on ClinicalTrials.gov

Study of MGCD0103 Given Three Times Weekly in Patients With Relapsed and Refractory Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

74

Participants

Timeline

Start Date

August 31, 2006

Primary Completion Date

January 31, 2012

Study Completion Date

January 31, 2012

Conditions
Lymphoma
Interventions
DRUG

MGCD0103

MGCD0103 given orally three times per week

Trial Locations (5)

27710

Duke University Adult Bone Marrow Transplant Clinic, Durham

77030

MD Anderson Cancer Center, Houston

K1H 8L6

Ottawa Hospital - General Campus, Ottawa

J4V 2H1

Charles LeMoyne Hospital, Greenfield Park

H3T 1E2

Sir Mortimer Davis-Jewish General Hospital, Montreal

Sponsors
All Listed Sponsors
lead

Mirati Therapeutics Inc.

INDUSTRY

NCT00359086 - Study of MGCD0103 Given Three Times Weekly in Patients With Relapsed and Refractory Lymphoma | Biotech Hunter | Biotech Hunter